News

Bio-plastics startup wins Lighthouse Labs pitch contest

Charlottsville, VA (Virginia Business) – While pitching to the sharks, entrepreneur Alec Brewer told them, “I do have white powder in my pocket,” before quickly clarifying that it wasn’t an illicit substance: “It’s PHB! It’s PHB!”

The co-founder and CEO of Charlottesville-based biodegradable plastics manufacturer Ourobio, Brewer explained that his company makes PHB, or polyhydroxybutyrate, from waste in order to reduce microplastics pollution. Ourobio converts whey into PHB through a biochemical process.

Ourobio was voted “shark favorite” out of nine entrepreneurs in Richmond business accelerator Lighthouse Labs’ 2022 spring cohort that pitched to four business leaders as part of the accelerator’s biannual Demo Day competition May 24. Ourobio received $1,500 from sponsor ThinkNimble and will have naming rights to a tagged great white shark that Lighthouse Labs is sponsoring.

Founded in 2012, Lighthouse Labs is a mentor-driven nonprofit accelerator that runs two, 12-week cohort sessions each year, investing $20,000 equity-free in six to 10 early-stage startups. Entrepreneurs accepted into the program receive mentorship and education on scaling up their businesses. Lighthouse Labs has accelerated more than 80 companies during the last 10 years, providing more than $1.6 million in equity-free funding. The Demo Day pitch contest is the grand finale event for each cohort.

Llamawood CEO Hunter Garen won the audience vote in the Demo Day competition; for his prize, he was given the privilege of throwing the first pitch at a Richmond Flying Squirrels baseball game.

While the same may not be true for his throwing arm,  Garen started his business pitch with a flourish, tossing postcards with coupon codes into the first few rows. Llamawood connects firewood suppliers and purchasers.

“I designed for a woman … because, as they say, women’s standards are much higher than men’s, so if you design for a woman, you’ll make every man happy,” Garen joked when telling the sharks about his customer demographics.

Sharks judging the competition were: Ajay Kori of UrbanStems and Novilla Pharmaceuticals; Claire Herring of Blue Ocean Brain; Richard Wintsch of Startup Virginia; and Joy Polefrone with VCU Health.

Also pitching at the competition were founders of Richmond-based beauty company LipLoveLine; Philadelphia-based software manufacturer Viora Health; Fort Belvoir-based health tech company Kinometrix Inc.; Philadelphia-based health care tech firm Hoth Intelligence; Richmond-based Nessle, which operates an online platform for expectant  parents; Austin, Texas-based tech firm On-Time Trials; and Houston-based health care tech company CaseCTRL.

Read more here.

Recent News

08/25/2026

United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the FDA has accepted the New Drug Application (NDA) for ralinepag to treat PAH. The FDA has set a Prescription Drug User Fee Act target action date of June 24, 2027. Ralinepag has not been approved for use in any indication by the

08/19/2026

ATCC Receives New CDC Award to Advance Influenza Testing and Surveillance

ATCC has been selected by the Centers for Disease Control and Prevention (CDC) for a new contract to support serological assays for the detection and characterization of influenza viruses. The award, valued at up to $7.3 million over the 5-year contract period (contract 75D30126C21030), will support CDC’s National Center for Immunization and Respiratory Diseases, Influenza

08/18/2026

Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™

Nanochon, a medical device company developing Chondrograft™, a novel patented implant for the treatment of articular cartilage defects of the knee, today announced that it has received regulatory approval from Panamá’s Ministry of Health to initiate its First-in-Human (FIH) clinical study in Panamá. The study will evaluate the safety and performance of Chondrograft™ in patients